Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Authors
Keywords
-
Journal
DRUGS
Volume 81, Issue 16, Pages 1859-1879
Publisher
Springer Science and Business Media LLC
Online
2021-10-27
DOI
10.1007/s40265-021-01610-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
- (2021) Shaden Mahmmod et al. INFLAMMATORY BOWEL DISEASES
- An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch
- (2021) Raphael P. Luber et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
- (2020) Hans C. Ebbers et al. BIODRUGS
- The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
- (2020) HoUng Kim et al. DRUGS
- Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
- (2020) Justin Stebbing et al. JOURNAL OF CLINICAL ONCOLOGY
- P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
- (2020) S Mazza et al. Journal of Crohns & Colitis
- P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis
- (2020) Y Bouhnik et al. Journal of Crohns & Colitis
- Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
- (2020) Yoon-Kyoung Sung et al. PLoS One
- Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice
- (2020) Ambre Lauret et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
- (2020) Liese Barbier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn’s Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar
- (2020) Cristiano Pagnini et al. INFLAMMATORY BOWEL DISEASES
- Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
- (2020) Marie-Christine Bielsky et al. DRUG DISCOVERY TODAY
- Clinical trial and ‘real-world’ data support switching from a bio-originator to its biosimilar
- (2019) Jonathan Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- (2019) Byong Duk Ye et al. LANCET
- Timely Use of Biologics in Early Crohn’s Disease: The Return of “Hit Hard and Early”?
- (2019) Catherine Le Berre et al. DIGESTIVE DISEASES AND SCIENCES
- P.07.13 SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13
- (2019) R. Lovero et al. DIGESTIVE AND LIVER DISEASE
- Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- (2019) Gionata Fiorino et al. DIGESTIVE AND LIVER DISEASE
- Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
- (2019) Chien-Lung Tu et al. BIODRUGS
- Biosimilars in the Americas: the future by consensus
- (2019) Robert John Moots CLINICAL RHEUMATOLOGY
- Immunogenicity of infliximab and adalimumab
- (2019) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Mo1892 – Non-Medical Reverse Switch Between the Originator Infliximab and Its Biosimilar in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Therapeutic Drug Monitoring
- (2019) Lorant Gonczi et al. GASTROENTEROLOGY
- Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience
- (2019) Jonathan Barker et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Are There Benefits and Risks to Biosimilars from a Patient Perspective?
- (2019) Jonathan Kay RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
- (2019) Christopher J. Webster et al. BIODRUGS
- Are we ready to close the discussion on the interchangeability of biosimilars?
- (2019) Hans C. Ebbers et al. DRUG DISCOVERY TODAY
- Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach
- (2019) Laurent Peyrin-Biroulet et al. Expert Review of Gastroenterology & Hepatology
- Evolution of the EU Biosimilar Framework: Past and Future
- (2019) Elena Wolff-Holz et al. BIODRUGS
- An Efficient Development Paradigm for Biosimilars
- (2019) Christopher J. Webster et al. BIODRUGS
- Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
- (2019) Vibeke Strand et al. BIODRUGS
- An update on the animal studies conducted for biosimilar approvals – Regulatory requirement vs actual scenario
- (2019) Parag Pipalava et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- (2019) Binita Dutta et al. BIODRUGS
- Pragmatic rules for comparability of biological medicinal products
- (2019) R. Martijn van der Plas et al. BIOLOGICALS
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
- (2018) Bassel El Zorkany et al. CLINICAL RHEUMATOLOGY
- Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
- (2018) Paul Declerck et al. CLINICAL THERAPEUTICS
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- Progress with infliximab biosimilars for inflammatory bowel disease
- (2018) Zsuzsanna Kurti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review
- (2018) Javier P. Gisbert et al. Gastroenterologia y Hepatologia
- Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
- (2018) Gionata Fiorino et al. INFLAMMATORY BOWEL DISEASES
- P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimised therapeutic drug monitoring assays
- (2018) F Magro et al. Journal of Crohns & Colitis
- Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
- (2018) Siddharth Singh et al. PLoS One
- The Science Behind Biosimilars
- (2018) S. Louis Bridges et al. Arthritis & Rheumatology
- Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
- (2018) Syed Numan et al. ADVANCES IN THERAPY
- Practical Guidance on Biosimilars, With a Focus on Latin America
- (2018) Valderilio Feijó Azevedo et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Use of Biosimilars in Paediatric Inflammatory Bowel Disease
- (2018) Lissy de Ridder et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
- (2018) Brian G. Feagan et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
- (2018) Beate Beyer et al. Biotechnology Journal
- Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
- (2018) Niels S. Vermeer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review
- (2018) Georgios Bakalos et al. CLINICAL THERAPEUTICS
- Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
- (2018) María Fernanda Guerra Veloz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- IBD: To switch or not to switch: that is the biosimilar question
- (2017) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
- (2017) Hendrik Schulze-Koops et al. RHEUMATOLOGY
- Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
- (2017) Till Uhlig et al. RHEUMATOLOGY
- Insights on the use of biosimilars in the treatment of inflammatory bowel disease
- (2017) Michael K Zheng et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
- (2017) Robert Moots et al. Current Rheumatology Reports
- Clinical trials of biosimilars should become more similar
- (2016) Jonathan Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
- (2016) M Begoña Ruiz-Argüello et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Switching Between Epoetins: A Practice in Support of Biosimilar Use
- (2016) Carmen D’Amore et al. BIODRUGS
- Assessing the Immunogenicity of Biopharmaceuticals
- (2016) Carlos Pineda et al. BIODRUGS
- Japanese regulation of biosimilar products: past experience and current challenges
- (2016) Teruyo Arato BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The design of clinical trials to support the switching and alternation of biosimilars
- (2016) Freddy Faccin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Biosimilars in IBD: from theory to practice
- (2016) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
- (2015) Shomron Ben-Horin et al. GUT
- Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
- (2013) Keith Bodger et al. GUT
- The safety of switching between therapeutic proteins
- (2012) Hans C Ebbers et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started